|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **MODULE 1: ADMINISTRATIVE INFORMATION** | | | | | | | | |
| 1. PARTICULARS OF THE PRODUCT | | | | | | | | |
|  | Type of the product application  New  Biosimilar  Renewal\*  \* If variation has been made, information supporting the changes should be submitted. See variation guidelines for registered products. | | | | | | | |
|  | Proprietary Name | | | | | | | |
|  | International Non-proprietary Name (INN) of the Drug substance | | | | | | | |
|  | Strength of Drug substance per unit dosage form: | | | | | | | |
|  | Name and address (physical and postal) of Applicant | | | | | | | |
| (Company) Name:  Address:  Country:  Telephone:  Email: | | | | | | | | |
|  | Name and address (physical and postal) of Local Technical Representative: | | | | | | | |
| (Company) Name:  Address:  Country:  Telephone:  Email: | | | | | | | | |
|  | Pharmaceutical Dosage form and route of administration | | | | | | | |
| Dosage form: | | | | | | | | |
| Route(s) of administration (use current list of standard terms) | | | | | | | | |
|  | Packing/pack size: | | | | | | | |
|  | Visual description  (Add as many rows as necessary) | | | | | | | |
|  | Proposed shelf life (in months): | | | | | | | |
|  | Proposed shelf life (after reconstitution or dilution): | | | | | | | |
|  | Proposed shelf life (after first opening container): | | | | | | | |
|  | Proposed storage conditions: | | | | | | | |
|  | Proposed storage conditions after first opening: | | | | | | | |
|  | Other sister products registered or applied for registration | | | | | | | |
|  | Do you hold Marketing Authorization (s) of other product (s) containing the same active pharmaceutical ingredient(s) in the EAC?  If yes state; Product name (s), strength (s), pharmaceutical form (s):  Partner States where product is authorized:  Marketing authorization number(s):  Indication(s): | | | | | | | |
|  | Have you applied for Marketing Authorization of product(s) containing the same drug substance (s) in the EAC?  Product name (s), strength (s), pharmaceutical form (s):  Indication(s): | | | | | | | |
|  | Pharmacotherapeutic group and ATC Code | | | | | | | |
|  | Pharmacotherapeutic group | | | | | | | |
|  | ATC Code: (Please use current ATC code) | | | | | | | |
|  | If no ATC code has been assigned, please indicate if an application for ATC code has been made: Yes  No  *(to select applicable box, double click on the box and select “checked”)* | | | | | | | |
|  | Distribution category: Controlled Drug  POM  Pharmacy Only  OTC  General sale  (Applicants are invited to indicate which categories they are requesting, however, the Authority reserve the right to change and/or apply only those categories provided for in their national legislation) | | | | | | | |
|  | Country of origin: | | | | | | | |
|  | Product Marketing Authorization in the country of origin (Attach Certificate of Product from National Medicines Regulatory Authority). If not registered, state reasons | | | | | | | |
| Authorized  Country:  Date of authorization (dd-mm-yyyy):  Proprietary name:  Authorization number:  Refused  Country:  Date of refusal (dd-mm-yyyy):  Reason for Refusal: | | | | | | Withdrawn (by applicant after authorization)  Country:    Date of withdrawal (dd-mm-yyyy):  Proprietary name:  Reason for withdrawal:  Suspended/revoked (by competent authority)  Country:  date of suspension/revocation (dd-mm-yyyy):  Reason for suspension/revocation:  Proprietary name: | | |
|  | List ICH countries and Observers where the product is approved. | | | | | | | |
|  | Name(s) and complete physical address(es) of the manufacturer(s) | | | | | | | |
|  | Name(s) and physical address (es) of the manufacturing site of the drug product, including the final product release if different from the manufacturer. Alternative sites should be also declared here.  All manufacturing sites involved in the manufacturing process of each step of the finished product, stating the role of each including quality control / in-process testing sites should be listed.  (Add as many rows as necessary | | | | | | | |
| Name:  Company name:  Address:  Country:  Telephone:  E-Mail: | | | | | | | | |
|  | | Name(s) and physical address(es) of the manufacturer(s) of the drug substance  (Add as many rows as necessary)  All manufacturing sites involved in the manufacturing process of each source of active substance, including quality control / in-process testing sites should be listed. | | | | | | |
| Name:  Company name:  Address:  Country:  Telephone:  E-Mail: | | | | | | | | |
|  | | Name and address (physical and postal) of the person or company responsible for Pharmacovigilance | | | | | | |
| Name:  Company name:  Address:  Country:  Telephone:  E-Mail: | | | | | | | | |
|  | | State the reference/monograph standard such as British Pharmacopeia, United States Pharmacopeia, Ph. Eur, Japanese Pharmacopeia, In-house monograph e.t.c. used for Drug Product. | | | | | | |
|  | | Qualitative and Quantitative composition of the drug substance(s) and excipient(s)  A note should be given as to which quantity the composition refers (e.g. 1 capsule). | | | | | | |
| Name of drug substance(s)\* | | | | | Quantity / dosage unit | | Unit of measure | Reference/ monograph standard |
|  | | | | |  | |  |  |
|  | | | | |  | |  |  |
|  | | | | |  | |  |  |
| Name of excipient(s) | | | | | | | | |
|  | | | | |  | |  |  |
|  | | | | |  | |  |  |
|  | | | | |  | |  |  |
| Note: \* Only one name for each substance should be given in the following order of priority: INN\*\*, Pharmacopoeia, common name, scientific name  \*\* The drug substance should be declared by its recommended INN, accompanied by its salt or hydrate form if relevant.  Details of averages should not be included in the formulation columns but should be stated below:  - Drug substance(s):  - Excipient(s): | | | | | | | | |
|  | | | Name and address (physical and postal) of the Contract Research Organisation(s) where the clinical studies of the product were conducted | | | | | |
| Name:  Company name:  Address:  Country:  Telephone:  E-Mail: | | | | | | | | |
|  | | | | Name and address (physical and postal) of the site(s) where the non- clinical studies of the product were conducted | | | | |
| Name:  Company name:  Address:  Country:  Telephone:  E-Mail: | | | | | | | | |
| **2.0 DECLARATION BY AN APPLICANT** | | | | | | | | |
| I, the undersigned certify that all the information in this form and accompanying documentation is correct, complete and true to the best of my knowledge.  I further confirm that the information referred to in my application dossier is available for verification during GMP inspection.  I also agree that I shall carry out pharmacovigilance to monitor the safety of the product in the market and provide safety update reports to the Authority.  I further agree that I am obliged to follow the requirements of the Legislations and Regulations, which are applicable to products.  I also consent to the processing of information provided by the Authority.  It is hereby confirmed that fees will be paid/have been paid according to the National/Community rules\*  Name: ……………………………………………………………………………….  Position in the company:…………………………………………………………  Signature: …………………………………………………………………………  Date:………………………………………..  Official stamp:……………………………..  \* Note: If fees have been paid, attach proof of payment | | | | | | | | |